Doc. #120136v1

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 type a plus sign (+) inside this box -> + U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 9 Winder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/040.319 Applicati n Number TRANSMITTAL Filing Date January 2, 2002 **FORM** First Named Inventor Becker, Cyrus Kephra et al. (to be used for all correspondence after initial filing) Group Art Unit 1624 Examiner Name Ford, John M. Total Number of Pages in This Submission **Attorney Docket** 3 **R0079C-REG** Number ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form (for an Application) **G**roup Re. Fees, pls. see under Appeal Communication to Board of FEB 2 1 2003 Appeals and Interferences Drawing(s) Remarks Appeal Communication to Group Amendment / Response to Notice, Brief, Reply Brief) Licensing-related Papers Restriction Requirement **TECH CENTER 16** Petition After Final Proprietary Information Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Associate Power of Attorney Other Enclosure(s) Extension of Time Request (please identify below): **Acknowledgement** Terminal Disclaimer Express Abandonment Request **Postcard** Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Applicants believe that no fees are due. However, should this not Response to Missing Parts/ Incomplete Application be the case, please charge any additional fees that may be required to Deposit Account No. 18-1700. Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Anastasia Winslow Registration No. 40,875 Firm Roche Palo Alto LLC, M/S A2-250 Individual name 3401 Hillview Avenue, Palo Alto, CA 94304 PATENT TRADEMARK OFFICE Signature Date February 13, 2003 **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.: Typed or printed name Weise Date Signature

## ATTORNEY DOCKET NO. R0079C-REC

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8** 

tereby certify that this paper is being deposited with the U.S. Postal Service under 37 CFR 1.8 as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington D.C. 20231, on the date indicated below.

our Weise

Name of Person Mailing: Iris Weise

\_\_\_\_\_\_Date: <u>2-/</u>3-03

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Becker et al.

Serial No.: 10/040,319

Filed: Jan. 2, 2002

**QUINAZOLONE DERIVATIVES AS** 

ALPHA 1A/B ADRENERGIC RECEPTOR

**ANTAGONISTS** 

Group Art Unit: 1624 Examiner: Ford, John M. EVED

FEB 2 1 2003

**TECH CENTER 1600/2900** 

COMMISSIONER FOR PATENTS Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action mailed February 6, 2003, having a one-month shortened statutory response time due to expire on March 6, 2003, please consider the remarks below.

## REMARKS

The Examiner requires restriction to one of the following inventions under 35 U.S.C.

121:

- instances in claims 1-39 where Z is -C(=O)-; and **(I)**
- instances in claims 1-39 where Z is  $-S(O)_{2}$ . (II)

Applicant provisionally elects, with traverse, the compounds of Group I, drawn to compounds where Z is -C(=O)-. Applicant does not dispute the finding that the compounds Serial No. 10/040,319

falling into Groups I and II reflect distinct inventions. However, applicant contends that a search and examination could be performed on the entire claim without serious burden and thus, restriction should not be required pursuant to MPEP §§ 803, 803.02. In particular, § 803 provides:

If the search and examination of an entire application can be made without serious burden, the examiner *must* examine it on the merits, even though it includes claims to independent or distinct inventions [MPEP §§ 803].

Likewise, § 803.02 provides:

If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions [MPEP § 803.02].

Applicant submits it would not present a serious burden to examine compounds where Z is sulfonyl along with compounds where Z is carbonyl in that both have a common oxygen atom (=O) bonded at the some position of the quinazolone core. Without waiver of the foregoing, Applicant elects the Group I compounds and reserves the right to file one or more divisional applications directed to the originally presented subject matter.

Search and examination of this application is earnestly solicited. The Examiner is invited to contact the undersigned by telephone to expedite prosecution of this application.

Respectfully submitted,

1. P. Wirlim

Anastasia P. Winslow Reg. No. 40,875

Roche Palo Alto LLC Patent Law Dept. M/S A2-250 3401 Hillview Avenue Palo Alto, CA 94304

Direct Phone: (650) 852-1141 Date: February 13, 2003